Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

71.72
+0.80001.13%
Volume:577.32K
Turnover:41.28M
Market Cap:4.02B
PE:6.46
High:71.72
Open:70.93
Low:70.93
Close:70.92
52wk High:74.59
52wk Low:59.47
Shares:56.10M
Float Shares:56.10M
Volume Ratio:9.11
T/O Rate:1.03%
Dividend:0.81
Dividend Rate:1.13%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.44
PE(LYR):23.44

Loading ...

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Judge Denies In Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.

Dow Jones
·
Oct 01

Judge Denies in Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
Oct 01

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Oct 01

Exchange-Traded Funds Higher, US Equities Mixed After Midday

MT Newswires Live
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence

TIPRANKS
·
Oct 01

AbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage Pipeline

TIPRANKS
·
Oct 01

Trump Pledges $500 Rebates to 1 Million Medicare Beneficiaries Each, to Be Mailed Starting Oct. 1

TradingKey
·
Sep 30

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30